A Pilot Study of Risk-Guided Cardioprotection with Carvedilol in Breast Cancer Patients Treated with Doxorubicin and/or Trastuzumab

Brief description of study

Subjects with breast cancer starting treatment with anthracyclines/trastuzumab will be enrolled and their risk of cardiotoxicity calculated. If elevated risk, they will be randomized to intervention with carvedilol for 1 year vs usual care. Low risk subjects will be usual care. All subjects will be followed with serial echo, survey, and blood draws.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    breast cancer
  • Age: - 99 Years
  • Gender: All
Updated on 29 Jan 2020. Study ID: 832105

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center